Abstract
Background:
Although numerous studies have reported the association between tertiary lymphoid structures (TLSs) and clinical outcomes in cancer patients treated with immune checkpoint inhibitors (ICIs), there remains a lack of a newer and more comprehensive meta-analysis. The main objective of this study is to explore prognostic biomarkers in immunotherapy-related patients, through analyzing the associations between tertiary lymphoid structures (TLSs) and clinical outcomes in cancer patients treated with ICIs, so as to investigate their prognostic value in cancer patients treated with ICIs.
Methods:
A comprehensive search was conducted until February 2024 across PubMed, Embase, Web of Science, and the Cochrane Library databases to identify relevant studies evaluating the association between tertiary lymphoid structures and clinical outcomes in cancer patients treated with ICIs. The clinical outcomes were overall survival (OS), progression‐free survival (PFS), and objective response rate (ORR).
Results:
Thirteen studies were incorporated in this meta-analysis, among which nine evaluated the prognostic value of TLSs. The results showed the high levels of TLSs predicted a significantly prolonged OS (pooled HR = 0.35, 95% CI: 0.24–0.53, p < 0.001) and PFS (pooled HR = 0.47, 95% CI: 0.31–0.72, p < 0.001), while lower ORR (pooled OR = 3.78, 95% CI: 2.26–6.33, p < 0.001) in cancer patients treated with ICIs.
Conclusion:
Our results indicated that high levels of TLSs could predict a favorable prognosis for cancer patients treated with ICIs and have the potential to become a prognostic biomarker of immunotherapy-related patients.
1 Introduction
Recently, exciting progress in cancer immunotherapy has ushered in a new era in cancer treatment, especially in the therapeutic domain of numerous solid tumors (1). The immune checkpoint inhibitors (ICIs) mainly included anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed cell death-1/programmed death ligand-1 (PD-1/PD-L1) (2). ICIs have improved patient survival in solid tumors, such as melanoma, non-small cell lung cancer, metastatic urinary tract carcinoma, hepatocellular carcinoma, gastric cancer (3–6). However, not all cancer patients benefit from immunotherapy. For instance, only approximately 5% of patients with metastatic triple-negative breast cancer obtain a positive response to PD-1/PD-L1 blockade (7, 8). Therefore, investigation of the corresponding biomarkers predicting immunotherapy response is of great significance for cancer patients.
Tertiary lymphoid structures (TLSs) are ectopic lymphoid organs formed in nonlymphoid tissues during chronic inflammation and tumorigenesis, which include B cells and T cells (9). The immune cells present in TLSs enhance the presentation of tumor antigens, amplify signaling through cytokines, and activate CD8+ T cells to target and destroy tumor cells (10, 11). TLSs play a crucial role as the focal points for triggering and sustaining both local and systemic T and B cell responses to tumors. TLSs identified from several solid tumors have been demonstrated to be correlated with the outcomes in cancer patients treated with ICIs (11–19). In general, the presence or a higher density of TLSs is an indicator of a favorable prognosis in cancer patients treated with ICIs (11–16, 18). Notably, a few studies also reported TLSs presence was not significantly associated with either PFS or OS in cancer patients treated with ICIs, such as head and neck squamous cell carcinoma and colorectal cancer (20, 21).
However, there is a lack of uniform standards for TLSs evaluation. Various studies have adopted different criteria, with some categorizing TLSs as either high or low density (22–24), and others using the mere existence or non-existence of TLSs as a benchmark for evaluation (23, 25). Additionally, the degree of TLSs maturity is a factor considered in some studies (26). The diversity in these classification methods may influence the prognostic predictive power associated with TLSs. Therefore, it is necessary to conduct a newer and more comprehensive meta-analysis to explore the association between tertiary lymphoid structures (TLSs) and clinical outcomes in cancer patients treated with ICIs. The main objective of this study is to explore prognostic biomarkers in immunotherapy-related patients, through analyzing the associations between tertiary lymphoid structures (TLSs) and clinical outcomes in cancer patients treated with ICIs, so as to investigate their prognostic value in cancer patients treated with ICIs.
2 Methods
2.1 Search strategy
This meta-analysis and systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines (27) and the protocol for the analysis was registered prospectively in PROSPERO (CRD42024504778). A comprehensive search was conducted on multiple databases including PubMed, Web of Science, the Cochrane Library, and Embase to identify relevant studies published until February 2024. The search terms included tertiary lymphoid structures (TLSs), tertiary lymphoid organ (TLO), tertiary lymphoid tissue (TLT), ectopic lymphoid-like structures (ELSs), cancer/tumor/solid tumor, immunotherapy, ICI, immune checkpoint inhibitor and prognosis, prognostic or survival outcome. The exact search query is provided as follows to allow reproducibility: (TLSs OR TLO OR TLT OR ELSs) AND (cancer OR tumor OR solid tumor) AND (prognosis OR prognostic OR survival outcome). Two researchers (LLL and YSG) independently screened titles and abstracts based on the inclusion and exclusion criteria. Finally, studies that provide reference data needed by this meta-analysis were selected through full-text reading, and discussions with a third author (BXG) were conducted when disagreements occurred between the two researchers (LLL and YSG).
2.2 Study selection
Original studies eligible for inclusion in this meta-analysis had to meet the following criteria:(1) being limited to English articles, (2) studies investigating the TLSs in situ in tumor tissue by applying immunohistochemistry and H&E staining; (3) studies focusing on evaluating the prognostic value of TLSs in cancer patients treated with ICIs, and (4) reporting clinical outcomes such as overall survival (OS), progression-free survival (PFS), objective response rate (ORR). The exclusion criteria were as follows: (1) conference abstracts, letters to the editor, reviews, comments, and animal trials; (2) studies with sample sizes < 20, since a small sample size induces publication bias; and (3) work without raw data that could be traced.
2.3 Data extraction
The data extracted from the included studies encompassed various variables, including the publication year, name of the first author, region, the type of ICIs, the type of tumor, TLS detection methods, number of enrolled patients, clinical outcome measures, the radio of sex, Newcastle-Ottawa scale and type of study (Table 1). The hazard ratios (HRs) and their associated 95% confidence intervals (95% CIs) from univariate or multivariate analysis were extracted. The assessment of each study was conducted by two authors (LLL and GYS) independently using the Newcastle-Ottawa scale (NOS), ranging from 0 to 9. Studies with an NOS score ≥ 6 were classified as high-quality studies. The two authors independently conducted the process and had discussions with a third author (BXG) when disagreements occurred.
Table 1
| Year | Author | Region | Treatment | Tumor | Cut-off criteria | Number of patients | Outcome | Gender (male/fem ale) | Newcastle-Ottawa scale | Study design |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | Gavrielatou N | USA | Nivolumab | HNSCC | Presence | 50 | PFS;OS | / | 9 | P |
| 2023 | Hayashi Y | Japan | Nivolumab | EC | Density | 34 | ORR;PFS | 27/7 | 8 | R |
| 2023 | Komura K | Japan | Pembrolizumab | UC | Presence | 100 | PFS;OS;ORR | 78/22 | 7 | R |
| 2022 | Jieqiong Liu | China | Camrelzumab/apatinib | TNBC | Mean area | 34 | PFS;ORR | / | 8 | P |
| 2020 | Wenhao Xu | China | TKIs/ICIs | ccRCC | Degree of maturity | 230 | ORR | / | 8 | R |
| 2020 | Rita Cabrita | Sweden | anti-CTLA4/anti-PD1 | Melanoma | Signature score | / | OS | / | 8 | R |
| 2019 | Tuba N Gide | Australia | Nivolumab/Pembrolizumab/ Ipilimumab | Melanoma | Signature score | / | OS | / | 8 | R |
| 2017 | Riaz N | USA | Nivolumab | Melanoma | Signature score | / | OS | / | 8 | P |
| 2015 | Van Allen EM | USA | Ipilimumab | Melanoma | Signature score | / | OS | / | 8 | R |
Characteristics of included studies.
HNSCC, head and neck squamous cell carcinoma; EC, esophageal cancer; UC, urothelial carcinoma; TNBC, triple-negative breast cancer; ccRCC, clear cell renal cell carcinoma; PFS, progression-free survival; OS, overall survival; ORR, objective response rate; P, Prospective; R, Retrospective.
2.4 Statistical analyses
Statistical software R software (version 4.1.0) was used to perform the analysis, while HR and 95% CI data were log transformed and pooled. Before performing a meta-analysis containing studies with different types of cancer and different types of immune checkpoint inhibitors (ICIs), heterogeneity was assessed through the implementation of a chi-square test and the I2 metric. The I2 value serves as an indicator of the proportion of variability across the pooled estimates that can be attributed to statistical heterogeneity. Studies with an I2 value exceeding 50% were considered to exhibit significant heterogeneity, where a random effects model was used for the analysis. Potential sources of heterogeneity were identified through the utilization of Baujat plots, and subsequent sensitivity analyses were carried out by systematically excluding individual studies. While a fixed effects model was utilized when heterogeneity was low (I2<50%), where sensitivity analysis is not required. Subsequently, the forest maps were subsequently created, followed by a comprehensive description of the pooled HR or OR accompanied by its corresponding 95% confidence interval (CI). Subgroup analyses of OS, PFS and ORR were performed based on patients’ characteristics. Publication bias was evaluated by an inverted funnel plot and was quantified by Egger’s and Begg’s tests. A two-sided α of less than 0.05 was considered statistically significant.
3 Results
3.1 Study selection and characteristics
Using the described search strategy, a total of 461 non-duplicated studies were identified. After screening based on predetermined criteria, 13 studies were selected for further evaluation through abstract review in accordance with the inclusion criteria. Due to small sample sizes, the 4 studies (14, 17–19), were only included in the systematic review. Therefore, this meta-analysis selected 9 studies (11–13, 15, 16, 21, 28–30) investigating the correlation between TLSs and clinical outcomes in cancer patients treated with immune checkpoint inhibitors. Figure 1 shows the flow diagram for literature retrieval and selection.
Figure 1
The basic information and main characteristics of the 9 included studies were shown in Table 1. Among the 9 included studies, six cohorts had a retrospective study design, and three cohorts were prospectively designed or from prospective trials (12, 21, 29). Among the 9 included studies evaluating the prognostic value of TLSs in cancer patients treated with ICIs: 6 studies evaluated overall survival (OS) (11, 12, 21, 28–30), 3 studies evaluated progression‐free survival (PFS) (13, 16, 21), and 4 studies evaluated objective response rate (ORR) (12, 13, 15, 16). All the studies included in the analysis obtained moderately high scores on quality assessments conducted using the Newcastle-Ottawa Scale. Out of the 9 studies that were included, 4 studies focused on specific types of cancer, with melanoma being the most commonly reported tumor (11, 28–30). The ICIs used in the aforementioned studies included PD-1 antibody (pembrolizumab and nivolumab were commonly used), PD-L1 antibody, CTLA-4 antibody, and combination therapies including immunotherapy.
TLSs were divided into high levels and low levels based on different cut-off criteria. Among the 9 studies included in this analysis, different cut-off criteria corresponded to different HR. In the subsequent investigation of the relationship between TLSs and OS, PFS, and ORR, we established inclusion criteria. If a study employs two distinct TLS cut-off criteria, our preference was given to the hazard ratio (HR) associated with Density, Degree of maturity, or Maximal diameter. In cases where a study applies both Density and Degree of maturity, or Density and Maximal diameter for TLS grading, the HR linked to Density was the one we chose.
3.2 Prognostic value of TLSs in cancer patients treated with ICIs
Among the 9 studies selected for this meta-analysis, 6 studies reported the association between OS and TLSs (11, 13, 21, 28–30). Considering the low heterogeneity (I2 = 0%), a fixed effects model was used for analysis. Results indicated the pooled HR was 0.35 (95% CI: 0.24–0.53, p < 0.001, Figure 2), suggesting the prognostic role of TLSs in cancer patients treated with ICIs.
Figure 2
The sensitivity analysis confirmed the pooled results’ credibility and stability. The funnel plots exhibited approximate symmetry (Figure 3A). Egger’s and Begg’s tests showed no significant publication bias (p = 0.154, p = 0.851), indicating that high levels of TLSs significantly predicted prolonged OS in cancer patients treated with ICIs.
Figure 3
Among the 9 studies selected for the meta-analysis, 3 studies reported the association between PFS and TLSs (13, 16, 21). Considering the low heterogeneity (I2 = 0%), a fixed effects model was used for analysis. Results indicated the pooled HR was 0.47 (95% CI: 0.31–0.72, p < 0.001, Figure 4). The sensitivity analysis confirmed the pooled results’ credibility and stability. The funnel plots exhibited approximate symmetry (Figure 3B). Egger’s and Begg’s tests showed no significant publication bias (p = 0.489, p = 0.602), indicating that high levels of TLSs significantly predicted better PFS in cancer patients treated with ICIs.
Figure 4
The ORR was reported in 4 studies which included 398 cancer patients treated with ICIs (12, 13, 15, 16). The pooled OR was 3.78 (95% CI: 2.26–6.33, p < 0.001, I2 = 32%, Figure 5) suggesting that TLSs were associated with lower tumor response. Similar results were obtained after conducting a sensitivity analysis. The funnel plots exhibited approximate symmetry (Figure 3C). Egger’s and Begg’s tests showed no significant publication bias (p = 0.478, p = 0.174).
Figure 5
4 Discussion
In recent years, the role of TLSs in immunotherapy response to solid tumors has received extensive attention (11–19, 21, 28–31), with melanoma being the most commonly reported tumor (11, 17, 28–30). In general, the presence or a higher density of TLSs were predicting a significantly prolonged OS and PFS in cancer patients treated with ICIs. Notably, a few studies also reported TLS presence was not significantly associated with either PFS or OS in cancer patients treated with ICIs, such as head and neck squamous cell carcinoma and colorectal cancer (20, 21). Hence, we conducted this meta-analysis in an effort to comprehensively summarize the prognostic significance of TLSs in cancer patients treated with ICIs.
Thus far, this study included 9 studies and represented the largest meta-analysis comprehensively summarizing the prognostic value of TLSs in cancer patients treated with ICIs. Although two previous meta-analysis reported the prognostic value of TLSs in cancer patients treated with ICIs (20, 32), they only included gastrointestinal cancers or breast cancer. A more extensive literature search was done in this study and we included more data for various tumors and built a good basis for evaluating the prognostic value of TLSs in cancer patients treated with ICIs. Moreover, sensitivity analyses and Baujat plots were conducted to validate the stability of the obtained results. The clinical outcomes of our results included OS, PFS and ORR. A present or higher density of TLSs significantly predicted prolonged OS and PFS, and better tumor response in cancer patients treated with ICIs, which suggested that high levels of TLSs could predict a favorable prognosis for cancer patients treated with ICIs.
Our results indicated that high levels of TLSs could predict a favorable prognosis for cancer patients treated with ICIs and have the potential to become a prognostic biomarker of immunotherapy-related patients. Our study represents a significant contribution to the field, offering valuable implications for future clinical practice. Given the cost of immunotherapy and the potential for drug toxicity, clinician needed to screen which cancer patients are suitable for immunotherapy. Tertiary lymphoid structure is a readily available biomarker that can be obtained directly by HE staining of biopsy or excision samples, and its lower cost makes it more easily applicable in different clinical scenes and countries with different incomes.
However, this meta-analysis had several limitations. Firstly, there is a lack of uniform standards for TLSs evaluation. The diversity in these classification methods may influence the prognostic predictive power associated with TLSs. Secondly, part of the included studies are retrospective studies, which may lead to inevitable selection bias and confounding bias, but Baujat plots and sensitivity analyses were subsequently performed to validate the stability of results. Thirdly, there were fewer studies included in certain analyses, especially in the association between PFS and TLSs, with only 3 immunotherapy studies included, which may affect the evaluation of the role of TLSs in prognosis. Fourthly, this study only included data related to intratumoral TLSs, which may not fully reflect its predictive role in prognosis. These limitations can affect the interpretation of the identified significant associations between high levels of TLSs and clinical outcomes in cancer patients treated with ICIs. However, the results of this study were reliable because low heterogeneity was detected and publication bias was not observed among most of the results.
5 Conclusions
Our results indicated that high levels of TLSs could predict a favorable prognosis for cancer patients treated with ICIs and have the potential to become a prognostic biomarker of immunotherapy-related patients.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.
Author contributions
LL: Writing – review & editing. YG: Writing – original draft. BG: Writing – original draft. SW: Writing – original draft. MW: Writing – original draft. PS: Writing – original draft. SJ: Writing – original draft. LY: Writing – original draft, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Conflict of interest
Author PS was employed by Philips Healthcare.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
Marin-AcevedoJADholariaBSoyanoAEKnutsonKLChumsriSLouY. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. (2018) 11:39. doi: 10.1186/s13045-018-0582-8
2
YarchoanMJohnsonBA3rdLutzERLaheruDAJaffeeEM. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. (2017) 17:209–22. doi: 10.1038/nrc.2016.154
3
GouMQianNZhangYWeiLFanQWangZet al. Construction of a nomogram to predict the survival of metastatic gastric cancer patients that received immunotherapy. Front Immunol. (2022) 13:950868. doi: 10.3389/fimmu.2022.950868
4
ParentPAuclinEPatrikidouAMezquitaLMartínez ChanzáNDumontCet al. Prognostic value of the lung immune prognosis index score for patients treated with immune checkpoint inhibitors for advanced or metastatic urinary tract carcinoma. Cancers (Basel). (2023) 15. doi: 10.3390/cancers15041066
5
SunTGuoYSunBChenLRenYZhuLet al. Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma. Eur J Med Res. (2023) 28:225. doi: 10.1186/s40001-023-01198-0
6
XieJChenMHanHXuKQiuGLinXet al. Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study. Thorac cancer. (2023) 14:1327–38. doi: 10.1111/1759-7714.14874
7
AdamsSLoiSToppmeyerDCesconDWDe LaurentiisMNandaRet al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. (2019) 30:405–11. doi: 10.1093/annonc/mdy518
8
DirixLYTakacsIJerusalemGNikolinakosPArkenauHTForero-TorresAet al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. (2018) 167:671–86. doi: 10.1007/s10549-017-4537-5
9
FridmanWHMeylanMPetitprezFSunCMItalianoASautès-FridmanC. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol. (2022) 19:441–57. doi: 10.1038/s41571-022-00619-z
10
Sautès-FridmanCPetitprezFCalderaroJFridmanWH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. (2019) 19:307–25. doi: 10.1038/s41568-019-0144-6
11
CabritaRLaussMSannaADoniaMSkaarup LarsenMMitraSet al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. (2020) 577:561–5. doi: 10.1038/s41586-019-1914-8
12
LiuJWangYTianZLinYLiHZhuZet al. Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer. Nat Commun. (2022) 13:3011. doi: 10.1038/s41467-022-30569-0
13
KomuraKTokushigeSIshidaMHirosunaKYamazakiSNishimuraKet al. Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab. Cancer science. (2023) 114:4622–31. doi: 10.1111/cas.15976
14
MoriTTanakaHDeguchiSYamakoshiYMikiYYoshiiMet al. Clinical efficacy of nivolumab is associated with tertiary lymphoid structures in surgically resected primary tumors of recurrent gastric cancer. PLoS One. (2022) 17:e0262455. doi: 10.1371/journal.pone.0262455
15
XuWLuJTianXYeSWeiSWangJet al. Unveiling the impact of tertiary lymphoid structures on immunotherapeutic responses of clear cell renal cell carcinoma. MedComm. (2024) 5:e461. doi: 10.1002/mco2.461
16
HayashiYMakinoTSatoEOhshimaKNogiYKanemuraTet al. Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors. Br J cancer. (2023) 128:2175–85. doi: 10.1038/s41416-023-02235-9
17
MoZLiuJZhangJDengYXuMJiangY. Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma. Int Immunopharmacol. (2023) 124:110973. doi: 10.1016/j.intimp.2023.110973
18
ShangTJiangTLuTWangHCuiXPanYet al. Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma. Front Immunol. (2023) 14:1166497. doi: 10.3389/fimmu.2023.1166497
19
ShuDHHoWJKagoharaLTGirgisAShinSMDanilovaLet al. Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockade. bioRxiv. (2023). doi: 10.1101/2023.10.16.562104
20
YuACaoMZhangKYangYMaLZhangXet al. The prognostic value of the tertiary lymphoid structure in gastrointestinal cancers. Front Immunol. (2023) 14:1256355. doi: 10.3389/fimmu.2023.1256355
21
GavrielatouNFortisESpathisAAnastasiouMEconomopoulouPFoukasGRPet al. B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma. Ann Oncol. (2023) 35(4):340–50. doi: 10.1016/j.annonc.2023.12.011
22
PoschFSilinaKLeiblSMündleinAMochHSiebenhünerAet al. Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. Oncoimmunology. (2018) 7:e1378844. doi: 10.1080/2162402x.2017.1378844
23
SchweigerTBerghoffASGlognerCGlueckORajkyOTraxlerDet al. Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer. Clin Exp metastasis. (2016) 33:727–39. doi: 10.1007/s10585-016-9813-y
24
YuJSHuangWBZhangYHChenJLiJFuHFet al. The association of immune cell infiltration and prognostic value of tertiary lymphoid structures in gastric cancer. Neoplasma. (2022) 69:886–98. doi: 10.4149/neo_2022_220128N123
25
ChengNLiPChengHZhaoXDongMZhangYet al. Prognostic value of tumor-infiltrating lymphocytes and tertiary lymphoid structures in Epstein-Barr virus-associated and -negative gastric carcinoma. Front Immunol. (2021) 12:692859. doi: 10.3389/fimmu.2021.692859
26
YinYXLingYHWeiXLHeCYWangBZHuCFet al. Impact of mature tertiary lymphoid structures on prognosis and therapeutic response of Epstein-Barr virus-associated gastric cancer patients. Front Immunol. (2022) 13:973085. doi: 10.3389/fimmu.2022.973085
27
MoherDLiberatiATetzlaffJAltmanDG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. (2009) 6:e1000097. doi: 10.1371/journal.pmed.1000097
28
GideTNQuekCMenziesAMTaskerATShangPHolstJet al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy. Cancer Cell. (2019) 35:238–55. doi: 10.1016/j.ccell.2019.01.003
29
RiazNHavelJJMakarovVDesrichardAUrbaWJSimsJSet al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. (2017) 171:934–49.e16. doi: 10.1016/j.cell.2017.09.028
30
Van AllenEMMiaoDSchillingBShuklaSABlankCZimmerLet al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Sci (New York NY). (2015) 350:207–11. doi: 10.1126/science.aad0095
31
HelminkBAReddySMGaoJZhangSBasarRThakurRet al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. (2020) 577:549–55. doi: 10.1038/s41586-019-1922-8
32
ZhangNNQuFJLiuHLiZJZhangYCHanXet al. Prognostic impact of tertiary lymphoid structures in breast cancer prognosis: a systematic review and meta-analysis. Cancer Cell Int. (2021) 21:536. doi: 10.1186/s12935-021-02242-x
Summary
Keywords
cancer, immunotherapy, meta-analysis, prognosis, tertiary lymphoid structures
Citation
Li L, Guo Y, Gong B, Wang S, Wang MM, Sun P, Jiang S and Yang L (2024) Association between tertiary lymphoid structures and clinical outcomes in cancer patients treated with immune checkpoint inhibitors: an updated meta-analysis. Front. Immunol. 15:1385802. doi: 10.3389/fimmu.2024.1385802
Received
13 February 2024
Accepted
12 June 2024
Published
27 June 2024
Volume
15 - 2024
Edited by
Ileana Mauldin, University of Virginia, United States
Reviewed by
Jaya Lakshmi Thangaraj, University of California, San Diego, United States
Shahram Salek-Ardakani, Inhibrx, United States
Updates
Copyright
© 2024 Li, Guo, Gong, Wang, Wang, Sun, Jiang and Yang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lian Yang, yanglian@hust.edu.cn
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.